Search research articles
Contact Us
Filters
Showing results (151-160 of 190) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
JAMA Ophthalmology
|
September 19, 2014
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial
William G Christen, Robert J Glynn, J Michael Gaziano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation
Pierre Bohanes, Cathryn J Rankin, Charles D Blanke, et al.
JAMA Oncology
|
December 16, 2016
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Vincent Chung, Shannon McDonough, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Chen Yuan, Kaori Sato, Bruce W Hollis, et al.
Lancet (London, England)
|
March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer Communications (London, England)
|
May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
The Lancet. Oncology
|
November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Roy S Herbst, Mary W Redman, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 190) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
JAMA Ophthalmology
|
September 19, 2014
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial
William G Christen, Robert J Glynn, J Michael Gaziano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation
Pierre Bohanes, Cathryn J Rankin, Charles D Blanke, et al.
JAMA Oncology
|
December 16, 2016
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Vincent Chung, Shannon McDonough, Philip A Philip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Chen Yuan, Kaori Sato, Bruce W Hollis, et al.
Lancet (London, England)
|
March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
NPJ Precision Oncology
|
January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Sandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer Communications (London, England)
|
May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
The Lancet. Oncology
|
November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Roy S Herbst, Mary W Redman, Edward S Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 19